Avalyn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage studies are expected in 2027.
FibroGen drug pamrevlumab has failed a Phase 3 study testing it in the chronic lung disorder idiopathic pulmonary fibrosis. It’s the second trial failure for the drug in the past month and the company’s third Phase 3 failure in the past two months.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
The biggest rounds of recent biotech financings are from startups raising money to advance their research to the clinic. Here’s a look back at funding rounds from companies such as Abdera Therapeutics, Complement Therapeutics, and Enveda Biosciences.
Three months after Alentis Therapeutics’ lead program posted positive Phase 1 data, the biotech has raised cash to advance that program to mid-stage testing in fibrosis. The Series C financing will also support a cancer drug candidate ready to start human testing.
Capstan Therapeutics, a University of Pennsylvania spinout, is now out of stealth with technology that could enable new medicines that work by engineering cells inside of a patient. Penn biotech pioneers Carl June and Drew Weissman are among the scientific co-founders of this startup, which aims to develop therapies for fibrosis, cancer, inflammation, and genetic diseases.
Sonata Therapeutics is developing drugs that reprogram cellular microenvironments to send signals intended to have curative effects. Cancer is the initial focus of the biotech, which Flagship Pioneering formed by combining two of its preclinical portfolio companies.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Roche will provide $390 million in cash upfront and then provide milestone payments to acquire Promedior, which is developing a drug to treat a rare and fatal lung disease.
Venture capital firm Versant Ventures launched the company with a $20 million Series A funding round last year.
The Waltham, Massachusetts-based company will receive $100 million, in addition to potential undisclosed milestones and royalties.
Firm raises funding for RNAi therapy's clinical development from group of Chinese funds.
How to turn analytics into actual policy outcomes.
Biopharma vet Deborah Dunsire has joined Waltham, Massachusetts-based XTuit Pharmaceuticals, a startup targeting the microenvironments that protect and drive certain cancers and fibrotic diseases.
It plans to bring its idiopathic pulmonary fibrosis small molecule to the clinic in the next two years.
VP Donnie McGrath said at this week's RESI conference in Houston that Bristol-Myers Squibb is targeting heart failure, virology, immunoscience, rare disease and fibrosis.